147 related articles for article (PubMed ID: 4652593)
1. New platinum complexes with anti-tumour activity.
Connors TA; Jones M; Ross WC; Braddock PD; Khokhar AR; Tobe ML
Chem Biol Interact; 1972 Nov; 5(6):415-24. PubMed ID: 4652593
[No Abstract] [Full Text] [Related]
2. Platinum complexes: a new class of antineoplastic agents.
Leh FK; Wolf W
J Pharm Sci; 1976 Mar; 65(3):315-28. PubMed ID: 1263076
[No Abstract] [Full Text] [Related]
3. Studies on the mechanism of action of the tumour inhibitory triazenes.
Audette RC; Connors TA; Mandel HG; Merai K; Ross WC
Biochem Pharmacol; 1973 Aug; 22(15):1855-64. PubMed ID: 4722457
[No Abstract] [Full Text] [Related]
4. Structure and activity relationships of platinum complexes with anti-tumour activity.
Braddock PD; Connors TA; Jones M; Khokhar AR; Melzack DH; Tobe ML
Chem Biol Interact; 1975 Sep; 11(3):145-61. PubMed ID: 1157188
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
[TBL] [Abstract][Full Text] [Related]
6. New tumor-inhibiting metal complexes.
Keppler BK; Berger MR; Heim ME
Cancer Treat Rev; 1990 Sep; 17(2-3):261-77. PubMed ID: 2272042
[No Abstract] [Full Text] [Related]
7. [Cytostatic non-platinum metal complexes: new perspectives for the treatment of cancer?].
Köpf-Maier P
Naturwissenschaften; 1987 Aug; 74(8):374-82. PubMed ID: 3309682
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis-dichlorodiammino platinum(II) in mice bearing Lewis lung carcinoma.
Sava G; Giraldi T; Mestroni G; Zassinovich G
Chem Biol Interact; 1983 Jul; 45(1):1-6. PubMed ID: 6683595
[TBL] [Abstract][Full Text] [Related]
9. Effect of antitumor platinum compounds with trans geometry on the induction of cytotoxicity and cell cycle modifications.
Barletta A; Coluccia M; Nassi A; Pardiso A
Eur J Histochem; 1997; 41 Suppl 2():61-2. PubMed ID: 9859784
[No Abstract] [Full Text] [Related]
10. Anti-tumour activity of heavy transition metal complexes against hepatoma cells.
Dehand J; Jordanov J
Chem Biol Interact; 1975 Dec; 11(6):605-9. PubMed ID: 172246
[No Abstract] [Full Text] [Related]
11. [Antineoplastic activity of complex compounds of platinum(IV)].
Presnov MA; Zheligovskaia NN; Babkov AV; Konovalova AL; Budanova NS
Dokl Akad Nauk SSSR; 1976 JUL-AUG; 229(1):226-9. PubMed ID: 954573
[No Abstract] [Full Text] [Related]
12. [Antineoplastic properties of complex compounds of platinum(II)].
Presnov MA; Konovalova AL; Stetsenko AI; Ivanov VF; Iakovlev KI
Dokl Akad Nauk SSSR; 1976 Oct; 230(6):1357-9. PubMed ID: 976058
[No Abstract] [Full Text] [Related]
13. Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasms.
Sava G; Zorzet S; Giraldi T; Mestroni G; Zassinovich G
Eur J Cancer Clin Oncol; 1984 Jun; 20(6):841-7. PubMed ID: 6540184
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy of advanced murine myeloma and subsequent resistance to tumor cell challenge.
Teller MN; Bowie M; Mountain IM; Stock CC
J Natl Cancer Inst; 1974 Mar; 52(3):667-71. PubMed ID: 4857022
[No Abstract] [Full Text] [Related]
15. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the preclinical activity of budotitane in three different transplantable tumor systems, its lack of mutagenicity, and first results of clinical phase I studies.
Keppler BK; Heim ME; Flechtner H; Wingen F; Pool BL
Arzneimittelforschung; 1989 Jun; 39(6):706-9. PubMed ID: 2775338
[TBL] [Abstract][Full Text] [Related]
17. Design of metallocenic drugs.
Engel J; Schumacher W; Schönenberger H
IARC Sci Publ; 1986; (78):295-307. PubMed ID: 3583395
[TBL] [Abstract][Full Text] [Related]
18. Antitumour properties of dimethylsulphoxide ruthenium (II) complexes in the Lewis lung carcinoma system.
Sava G; Pacor S; Zorzet S; Alessio E; Mestroni G
Pharmacol Res; 1989; 21(5):617-28. PubMed ID: 2594617
[TBL] [Abstract][Full Text] [Related]
19. Water-soluble organometallic analogues of oxaliplatin with cytotoxic and anticlonogenic activity.
Benedetti M; Antonucci D; Migoni D; Vecchio VM; Ducani C; Fanizzi FP
ChemMedChem; 2010 Jan; 5(1):46-51. PubMed ID: 19950163
[No Abstract] [Full Text] [Related]
20. Growth characteristics of MOPC-315 plasmacytoma and response to anticancer agents.
Valeriote F; Lynch R; Berger NA; White E; Coulter D
J Natl Cancer Inst; 1981 Jun; 66(6):1083-8. PubMed ID: 7017213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
